CXCR4 and familial pancreatic carcinoma: Although anti-CXCR4 therapies are being developed, the value of CXCR4 overexpression in different tumors (as breast cancer, lung cancer, or pancreatic cancer) remains unclear and several studies have provided a non-significant association between CXCR4 expression and clinical outcome [21].